Fate Therapeutics (FATE) Cash & Equivalents (2012 - 2026)

Fate Therapeutics' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $39.6 million for Q1 2026.

• Quarterly Cash & Equivalents fell 11.91% year-over-year to $39.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.6 million (down 11.91% YoY) and the FY2025 annual result came in at $46.6 million, up 29.32% from the prior year.
• Cash & Equivalents was $39.6 million for Q1 2026 at Fate Therapeutics, down from $46.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $121.3 million in Q1 2024 and bottomed at $33.3 million in Q3 2023.
• A 5-year average of $51.3 million and a median of $42.0 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 188.72% — and 2025, when it sank 62.97%.
• Fate Therapeutics' Cash & Equivalents stood at $61.3 million in 2022, then plunged by 31.73% to $41.9 million in 2023, then dropped by 13.89% to $36.1 million in 2024, then climbed by 29.32% to $46.6 million in 2025, then decreased by 15.14% to $39.6 million in 2026.
• Business Quant data shows FATE's Cash & Equivalents at $39.6 million in Q1 2026, $46.6 million in Q4 2025, and $40.6 million in Q3 2025.